WallStSmart

Aveanna Healthcare Holdings Inc (AVAH)vsJohnson & Johnson (JNJ)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 3716% more annual revenue ($99.33B vs $2.60B). JNJ leads profitability with a 16.2% profit margin vs 10.6%. AVAH trades at a lower P/E of 10.4x. AVAH earns a higher WallStSmart Score of 61/100 (C+).

AVAH

Buy

61

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 5.7Quality: 3.5
Piotroski: 4/9Altman Z: 0.95

JNJ

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 8.5Value: 3.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVAHSignificantly Overvalued (-65.2%)

Margin of Safety

-65.2%

Fair Value

$4.83

Current Price

$12.24

$7.41 premium

UndervaluedFair: $4.83Overvalued

Intrinsic value data unavailable for JNJ.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVAH3 strengths · Avg: 9.3/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
36.8%10/10

Every $100 of equity generates 37 in profit

EPS GrowthGrowth
38.5%8/10

Earnings expanding 38.5% YoY

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$657.68B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
25.7%8/10

Strong operational efficiency at 25.7%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

Areas to Watch

AVAH3 concerns · Avg: 2.3/10
Price/BookValuation
9.3x4/10

Trading at 9.3x book value

Altman Z-ScoreHealth
0.952/10

Distress zone — elevated risk

Debt/EquityHealth
5.241/10

Elevated debt levels

JNJ4 concerns · Avg: 2.8/10
Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.072/10

Expensive relative to growth rate

P/E RatioValuation
41.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : AVAH

The strongest argument for AVAH centers on P/E Ratio, Return on Equity, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.

Bear Case : AVAH

The primary concerns for AVAH are Price/Book, Altman Z-Score, Debt/Equity. Debt-to-equity of 5.24 is elevated, increasing financial risk.

Bear Case : JNJ

The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.

Key Dynamics to Monitor

AVAH profiles as a value stock while JNJ is a mature play — different risk/reward profiles.

AVAH carries more volatility with a beta of 2.01 — expect wider price swings.

AVAH is growing revenue faster at 13.7% — sustainability is the question.

JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.

Bottom Line

AVAH scores higher overall (61/100 vs 54/100) and 13.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aveanna Healthcare Holdings Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Aveanna Healthcare Holdings Inc., a diversified home care platform company, offers private duty nursing (PDN) services, adult home health and palliative care, pediatric home therapy, and enteral nutrition services in the United States. The company is headquartered in Atlanta, Georgia.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?